Drilldown: Medicines

Pharmacopedia is being built in public. Pages may be incomplete.About this site

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Antiparkinsonian

or PDE5 Inhibitor

or Phenethylamine

Use the filters below to narrow your results.

None (26) · Akineton (1) · Apokyn (1) · Artane (1) · Azilect (1) · Cialis, Adcirca (1) · Cogentin (1) · Comtan (1) · Dostinex (1) · Eldepryl (1) · Levitra, Staxyn (1) · Neupro (1) · Nexus, Eroxan (historical, late-1980s through mid-1990s) (1) · Ongentys (1) · Parlodel (1) · Sinemet (1) · Stendra (1) · Symmetrel (1) · Tasmar (1) · Viagra, Revatio (1) · Xadago (1)

5-HT2A agonist (12) · 5-HT2A agonist; long duration (1) · 5-HT2A agonist; MAO inhibitor (1) · 5-HT2A agonist; milder than other 2C-x (1) · 5-HT2A partial agonist (1) · Central and peripheral COMT inhibitor (1) · D1/D2/D3 receptor agonist (1) · D2 agonist; D1 partial agonist (1) · D2 receptor agonist (1) · Dopamine precursor (1) · Dopamine precursor + DOPA decarboxylase inhibitor (1) · Extremely potent 5-HT2A agonist; vasoconstrictor (1) · Extremely potent 5-HT2A agonist; very long duration (1) · Irreversible selective MAO-B inhibitor (2) · MAO-B inhibitor; sodium channel blocker; glutamate release inhibitor (1) · Muscarinic receptor antagonist (1) · Muscarinic receptor antagonist; dopamine reuptake inhibitor (1) · NMDA antagonist; dopamine releasing agent (1) · Non-selective dopamine receptor agonist (1) · Once-daily COMT inhibitor (1) · Peripheral COMT inhibitor (1) · Potent 5-HT2A agonist (5) · Potent 5-HT2A agonist; no oral activity (1) · Potent 5-HT2A agonist; very long duration (1) · Selective inhibitor of PDE5 with a substantially longer half-life than other PDE5 inhibitors, allowing once-daily continuous dosing. (1) · Selective inhibitor of PDE5. Slightly higher PDE5/PDE6 selectivity vs sildenafil (less visual side effect) but more PDE1 cross-activity (occasional QT effects at high doses). (1) · Selective inhibitor of phosphodiesterase type 5 (PDE5), preventing cGMP breakdown in vascular smooth muscle. In the corpus cavernosum, potentiates the NO/cGMP cascade triggered by sexual stimulation. (1) · Selective inhibitor of phosphodiesterase type 5 (PDE5); increases cGMP in cavernous smooth muscle, producing erection in response to sexual stimulation. (1) · Selective M1 muscarinic antagonist (1) · Very potent 5-HT2A agonist; long duration (1)

None (42) · '"`UNIQ--vote-00000040-QINU`"' (1) · '"`UNIQ--vote-00000669-QINU`"' (1) · '"`UNIQ--vote-00000705-QINU`"', '"`UNIQ--vote-00000706-QINU`"' (1) · '"`UNIQ--vote-00000738-QINU`"', '"`UNIQ--vote-00000739-QINU`"', '"`UNIQ--vote-0000073A-QINU`"' (1)

None (42) · 10 mg PRN; 2.5–5 mg daily for continuous coverage / BPH (1) · 10 mg ~1 h before sexual activity (1) · 100 mg ~15 min before sexual activity (1) · 50 mg ~1 h before sexual activity (ED); 20 mg TID (PAH) (1)

None (42) · 2.5, 5, 10, 20 mg tabs (1) · 2.5, 5, 10, 20 mg tabs (Levitra); 10 mg ODT (Staxyn) (1) · 25, 50, 100 mg tabs (Viagra); 20 mg tabs and 10 mg/mL oral suspension (Revatio) (1) · 50, 100, 200 mg tabs (1)

None (42) · 100 mg/d (ED); 20 mg TID (PAH) (1) · 20 mg/d (1) · 20 mg/d (ED, PRN); 5 mg/d (daily / BPH); 40 mg/d (PAH) (1) · 200 mg/d (100 mg/d if on CYP3A4 inhibitors) (1)

None (41) · insufflated (1) · IV (Revatio) (1) · Oral (5) · PR (1)

None (41) · 30 min (1) · 30–60 min (1) · 45-75 min (oral) (1) · ~15 min (fastest of the PDE5 inhibitors) (1) · ~30 min (1)

None (41) · 4-8 h (1) · 4–5 h (1) · 4–6 h (1) · Up to 36 h ("the weekend pill") (1) · ~4 h (1)

None (41) · 4–5 h (1) · Not well characterized (1) · ~17.5 h (1) · ~4 h (1) · ~5 h (1)

None (41) · Not well characterized (1) · Rapid absorption; absolute bioavailability not formally established (1) · Reasonable (not formally established as a percentage) (1) · ~15% (extensive hepatic first-pass) (1) · ~40% (1)

None (41) · Category B (3) · Category C (not relevant; not used in women) (1) · Not established (1)

None (41) · Rx-only in US (4) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1)